WEEKEND CHAT.
I was able to catch up with two friends of mine on the weekend.
The three of us had a nice meal at a local pub and the conversation
quickly turn to IMU. The two of them are holders, one a significant
one, and the other is a pleb like me. When I say significant, he is
somewhere between 20 and 30 on the list. He is an ex broker that
still works part time in the finance industry. The disaster of this last
capital raise was a hot topic, but so were some of the past capital raises.
What we all agreed on was the big impact that the institutional shorters
have had on the share price.
hargeo, posted this paragraph on the week end that we believe to be 100 percent true.
TB got to disagree. The prevailing force without any question, is the institutional shorters. Our careless chairman continues to feed them with new stock in return for their cash. The most recent effort yielded $35m cash for the Imugene bank balance, at a cost of several hundred million market cap, did you read that, several hundred million capital value, which anyone on the register already feels the pain of. Not only does he try to protect their identity, they enter the register via nominee accounts and then it’s difficult to see what goes on. One thing that is a certainty is that more than 2% of the short positions were closed at the time the recent new placement was done - think about that.. ie they were already short and were then hand fed more stock to close out. The decision from management to do this is a sackable offence requiring instant removal of whoever was stupid enough to allow it. Make no mistake, the hostility toward retail holders is from within, and on that note, it’s no wonder some have decided to sell once they have figured out what’s actually going on, and has been for some.
Well said hargeo.
But if there is any good to come out of this last capital raise its got to be the great asset
that IMU have picked up. They now can go into an early registrational trail, and if all goes
well it will be ground breaking. So on that front we gave credit were credit is due.
The three of us also chatted about Hoppers good points. We are not Hopper bashes, we just
call it as we see it.
Hoppers ability to get the best of the best people on board is second to none. We gave him a
10 out of 10 for that. Starting years ago with LC, and many more since.
Dr Yuman Fong, Saul Priceman, Dr Jakob Dupont, Pravin Kaumaya, Ursula Wiedermann and
the list goes on, to many to mention here. As I have mention before, Hopper getting
LC was a magnificent move that will pay of bigtime in the end.
Another interesting topic we believe is extremely important is the connection between
IMU's team of experts and the FDA. A big part of our reasoning to invest in IMU is just
that. Yuman Fong has a great history with the FDA, and he is highly respected by them.
Dr Jakob Dupont knows the FDA like the back of his hand, and he is also very well
respected by them. LC just like Dupont has taken drugs from lab to commercialization,
once again she also knows the FDA like the back of her hand, and the hole lot of them
have importantly had good relations with the FDA.
To emphasize this point, lets look at another bio on the ASX.
I'm not going to mention there name but most here know who I'm talking about.
There phase three trail just failed again for the second time, the FDA nocked them
back again. Not because there IP is not good enough, but because they have not had
a great working relationship with the FDA. When the FDA request something to be done
in a certain way you do it that way, or come up with something better that they would
like, you don't work against them, you work with them, because once you go out of
line with a trail its very hard to get them back on board.
This is a strength that IMU have in spades, and credit were credit is due, Hopper has
been able to get the right people on board to do this.
One poster recently said that IMU is now too top heavy, and from afar it may look like
this, but Imu is now moving into another phase of there development and need to bring
on the right personal for the job at hand to be done properly.
One of the recent stars to come on board late last year was Dupont. He has taken
something like ten drugs from start up to FDA approval, a great move by the board
to appoint him. I have mentioned before that Dupont coming over at this point in time
is a very strong validation that IMU looks like taking drugs with big Pharemacuticails
all the way through to FDA approval.
He would have done his due diligence very carefully before coming over to IMU.
He has a big reputation and wouldn't want to Harnish that, he can smell a deal
a mile away and is an expert in his field and we are confident he is going to play
a major role in getting deals done, hopefully sooner than latter.
After finishing lunch with my two friends with a beer or two, we all agreed that we
are on the same page, we believe that IMU could be one of those once in a lifetime
investment. We can hear the jungle drums beating, and they are beating very loudly,
bring on the VAXINIA trail results, my friends and I can't wait.
GLTAH.
(20min delay)